When you blow out your birthday candles each year, you’re marking the passage of time but not necessarily the passage of age.

A test developed by a Madison company to better track cancer DNA in the blood stream will now be covered by Medicare.

A blood test to watch breast cancer’s ‘molecular clock’ could help track the growth of multiple tumors around the body and monitor how they are responding to treatment, new research suggests.

Change in Test Coverage. On March 31, 2023, MolDX -- a Medicare molecular diagnostic testing program administered by Palmetto GBA, a large Medicare administrative contractor -- released an article ...

The new test is based on the RNA genetic markers forkhead box P3 (FoxP3), granzyme B (GZMB), and perforin (PRF1). Earlier detection of transplant rejection may spur interventions that help to ...

For instance, more complex molecular tests that rely on anticoagulation techniques (which one of the two FDA-cleared MiniDraw devices is specifically built for) could theoretically help in ...

Bipolar disorder (once known as manic depression) is a mental disorder that causes unusual changes in mood, concentration, and energy or activity levels, which may make everdayl tasks difficult.

Researchers have developed a proof-of-concept technique that allows them to detect brain tumor biomarkers with a simple blood test, rather than a complicated, invasive surgical process. Hong Chen, a ...

Instead of taking just one blood sample following the peak VO2 test, the researchers gathered four post-exercise blood samples – at two, 15, 30, and 60 minutes after the session.

One company is already marketing its blood test, ... Cheaper, faster and better gene sequencing tools can reveal the unique molecular characteristics of the DNA shed into the blood by tumor cells.

Researchers have successfully developed a blood test for anxiety. The test examines biomarkers that can help them objectively determine someone’s risk for developing anxiety, the severity of ...

They found that a small number of biomarkers in the blood test successfully distinguished the women with knee OA from those without it, catching molecular signals of OA eight years before many of ...